+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Complement C5 Recombinant Monoclonal Antibody Market - Global Forecast 2025-2030- Product Image
Complement C5 Recombinant Monoclonal Antibody Market - Global Forecast 2025-2030- Product Image
Sale

Complement C5 Recombinant Monoclonal Antibody Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 186 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6118833
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Complement C5 recombinant monoclonal antibodies are shaping a new era in B2B bioscience, transforming how research, diagnostics, and therapeutics approach immune modulation. This market is defined by rapid innovation, regulatory complexity, and increasing emphasis on precision and partnership—making strategic insight indispensable for senior decision-makers.

Market Snapshot: Complement C5 Recombinant Monoclonal Antibodies

This sector exhibits robust growth as evolving molecular designs and applications drive adoption in both established and emerging markets. The complement C5 recombinant monoclonal antibody market is propelled by increased utilization across research laboratories, diagnostic developers, and biopharmaceutical producers. Notably, the introduction of advanced recombinant technologies and enhanced antibody engineering has fostered higher binding affinity, improved stability, and better manufacturing scalability. As a result, these antibodies have become integral to diagnostics and therapeutics focused on complement-mediated disorders, with industry players intensifying investment in automation, supply resilience, and translational applicability.

Scope & Segmentation of the Complement C5 Recombinant Monoclonal Antibody Market

This report categorizes and forecasts market revenues across broad and granular segments, clarifying growth opportunities by application, product, end user, research area, and region.

  • Application Areas: Companion and in vitro diagnostics; research (clinical and preclinical); therapeutic use cases.
  • Product Types: IgG1, IgG2, IgG3, IgG4 subclasses—facilitating tailored selections based on assay sensitivity and therapeutic profiles.
  • End Users: Academic and research institutions, contract research organizations, diagnostic laboratories, pharmaceutical and biotech companies.
  • Research Areas: Autoimmune disorders, infectious diseases, neurological disorders, oncology—highlighting versatile utility.
  • Regional Coverage: Americas (United States including key states, Canada, Mexico, Brazil, Argentina); Europe, Middle East & Africa (extensive country-level analysis); Asia-Pacific (China, India, Japan, Australia, Southeast Asian and East Asian countries).
  • Technologies Highlighted: Recombinant antibody engineering, bispecific constructs, antibody fragments, automation, and multiplexed diagnostic platforms.

Key Takeaways: Strategic Insights in Complement C5 Antibody Innovations

  • Adoption of multifunctional antibody designs is expanding the utility of complement C5 recombinant monoclonal antibodies beyond traditional applications, facilitating innovative platforms in both research and diagnostics.
  • Cross-sector collaborations between academia, biotech firms, and regulatory authorities are amplifying best practice alignment, enhancing the clinical relevance and reproducibility of antibody products.
  • Fragment-based and bispecific antibody formats are gaining traction, offering targeted payload delivery and tissue-specific complement modulation—key for next-generation therapies.
  • Differentiation among leading competitors hinges on proprietary engineering capabilities, scalable manufacturing, and strength in intellectual property protected offerings.
  • Segmentation by subclass (IgG1–IgG4) enables customized solutions to suit unique end-user requirements, underpinning procurement and partnership models in diverse institutional settings.

Tariff Impact: Effects of United States 2025 Tariffs on the Complement C5 Antibody Supply Chain

The implementation of United States tariffs in 2025 has increased complexity and costs in global complement C5 recombinant monoclonal antibody supply chains. Manufacturers are mitigating effects by diversifying sourcing, expanding domestic production, and optimizing inventory management to balance increased landed costs and ensure supply continuity. Distributors and end users are responding with adaptive procurement and strategic alliances, while broader industry efforts focus on policy engagement and seeking tariff exclusions for mission-critical bioreagents.

Methodology & Data Sources

This analysis integrates primary interviews with industry leaders and antibody developers, alongside comprehensive secondary research drawn from peer-reviewed literature, patent records, regulatory submissions, and scientific conferences. Data triangulation and rigorous peer review underpin the reliability and depth of insights presented.

Why This Report Matters: Benefits for Senior Decision-Makers

  • Gain clarity on the evolving competitive landscape and critical technology trends influencing market success.
  • Inform strategic planning with actionable segmentation and region-specific opportunity mapping.
  • Identify collaboration and innovation strategies essential for sustained leadership in complement C5 antibody development.

Conclusion

Complement C5 recombinant monoclonal antibodies are transforming approaches to immune modulation across research and clinical settings. Equipped with deep market and segmentation analysis, senior leaders can drive innovation, manage risks, and capitalize on emergent opportunities in this dynamic sector.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of complement C5 monoclonal therapies into combination treatment regimens for rare immune disorders
5.2. Emergence of biosimilar alternatives to established C5 inhibitors driving competitive pricing pressure
5.3. Growing adoption of subcutaneous complement C5 antibody formulations to enhance patient convenience and adherence
5.4. Innovative engineering of next generation C5 recombinant antibodies to improve safety and reduce dosing frequency
5.5. Expansion of complement C5 antibody therapeutic indications into neuroinflammatory and renal disease markets
5.6. Impact of manufacturing challenges on global supply and pricing of high-value C5 monoclonal therapies
5.7. Strategic collaborations between biotech innovators and pharmaceutical giants accelerating C5 inhibitor development pipelines
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Complement C5 Recombinant Monoclonal Antibody Market, by Application
8.1. Introduction
8.2. Diagnostic
8.2.1. Companion Diagnostics
8.2.2. In Vitro Diagnostics
8.3. Research Use
8.3.1. Clinical Research
8.3.2. Preclinical Research
8.4. Therapeutic
9. Complement C5 Recombinant Monoclonal Antibody Market, by Product Type
9.1. Introduction
9.2. IgG1
9.3. IgG2
9.4. IgG3
9.5. IgG4
10. Complement C5 Recombinant Monoclonal Antibody Market, by End User
10.1. Introduction
10.2. Academic & Research Institutes
10.3. Contract Research Organizations
10.4. Diagnostic Laboratories
10.5. Pharmaceutical & Biotech Companies
11. Complement C5 Recombinant Monoclonal Antibody Market, by Research Area
11.1. Introduction
11.2. Autoimmune Disorders
11.3. Infectious Diseases
11.4. Neurological Disorders
11.5. Oncology
12. Americas Complement C5 Recombinant Monoclonal Antibody Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Complement C5 Recombinant Monoclonal Antibody Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Complement C5 Recombinant Monoclonal Antibody Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AstraZeneca PLC
15.3.2. InflaRx N.V.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024 VS 2030 (%)
FIGURE 12. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET: RESEARCHAI
FIGURE 24. COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET: RESEARCHSTATISTICS
FIGURE 25. COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET: RESEARCHCONTACTS
FIGURE 26. COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY CLINICAL RESEARCH, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY CLINICAL RESEARCH, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRECLINICAL RESEARCH, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRECLINICAL RESEARCH, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY THERAPEUTIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG1, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG1, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG2, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG2, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG3, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG3, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG4, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG4, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 87. CANADA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 88. CANADA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 89. CANADA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 90. CANADA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 91. CANADA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 92. CANADA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 93. CANADA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 94. CANADA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 95. CANADA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. CANADA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. CANADA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 98. CANADA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 99. MEXICO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 100. MEXICO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 101. MEXICO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 102. MEXICO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 103. MEXICO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 104. MEXICO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 105. MEXICO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 106. MEXICO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 107. MEXICO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. MEXICO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. MEXICO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 110. MEXICO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. ARGENTINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 134. ARGENTINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 152. UNITED KINGDOM COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 154. UNITED KINGDOM COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 156. UNITED KINGDOM COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. UNITED KINGDOM COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 160. UNITED KINGDOM COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 161. GERMANY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 162. GERMANY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 163. GERMANY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 164. GERMANY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 165. GERMANY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 166. GERMANY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 167. GERMANY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 168. GERMANY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 169. GERMANY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. GERMANY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. GERMANY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 172. GERMANY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 173. FRANCE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 174. FRANCE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 175. FRANCE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 176. FRANCE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 177. FRANCE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 178. FRANCE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 179. FRANCE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 180. FRANCE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 181. FRANCE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. FRANCE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. FRANCE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 184. FRANCE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 187. RUSSIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 188. RUSSIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 189. RUSSIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 190. RUSSIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 191. RUSSIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 192. RUSSIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 193. RUSSIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. RUSSIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. RUSSIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 196. RUSSIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 197. ITALY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 198. ITALY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 199. ITALY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 200. ITALY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 201. ITALY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 202. ITALY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 203. ITALY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 204. ITALY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 205. ITALY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. ITALY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. ITALY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 208. ITALY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 209. SPAIN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 210. SPAIN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 211. SPAIN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 212. SPAIN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 213. SPAIN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 214. SPAIN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 215. SPAIN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 216. SPAIN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 217. SPAIN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. SPAIN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. SPAIN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 220. SPAIN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 236. SAUDI ARABIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 238. SAUDI ARABIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 240. SAUDI ARABIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. SAUDI ARABIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 244. SAUDI ARABIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 248. SOUTH AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 250. SOUTH AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 252. SOUTH AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. SOUTH AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 256. SOUTH AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 257. DENMARK COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 258. DENMARK COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 259. DENMARK COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 260. DENMARK COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 261. DENMARK COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 262. DENMARK COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 263. DENMARK COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 264. DENMARK COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 265. DENMARK COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. DENMARK COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. DENMARK COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 268. DENMARK COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 269. NETHERLANDS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 270. NETHERLANDS COMPLEMENT C5 RECOMBINANT MONOCLO

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Complement C5 Recombinant Monoclonal Antibody market report include:
  • AstraZeneca PLC
  • InflaRx N.V.

Related Topics

Related Reports

2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA - Product Image

2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA

  • Report
  • 84 Pages
  • Global
From
Vectorized Antibodies By In Vivo Expression Of DNA Or RNA: A Competitive Business, Stakeholder, Technology & Pipeline Analysis From an Industry Perspective - Product Image

Vectorized Antibodies By In Vivo Expression Of DNA Or RNA: A Competitive Business, Stakeholder, Technology & Pipeline Analysis From an Industry Perspective

  • Report
  • 381 Pages
  • Global
From
Rabies Virus Monoclonal Antibody Market - Global Forecast 2025-2030 - Product Image

Rabies Virus Monoclonal Antibody Market - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
In Vitro Antibody Production Service Market - Global Forecast 2025-2030 - Product Image

In Vitro Antibody Production Service Market - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Biopharmaceutical Market Report by Indication (Autoimmune Diseases, Oncology, Metabolic Disorders, and Others), Class (Recombinant Proteins, Monoclonal Antibodies, Purified Proteins), and Region 2025-2033 - Product Image

Biopharmaceutical Market Report by Indication (Autoimmune Diseases, Oncology, Metabolic Disorders, and Others), Class (Recombinant Proteins, Monoclonal Antibodies, Purified Proteins), and Region 2025-2033

  • Report
  • 145 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.